BUZZ-Oncolytics Biotech Inc: Presents cancer drug data at conference

Thu Mar 5, 2015 7:45am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian drug developer's U.S.-listed shares up 5 pct at $1.06 premarket

** Company presents data at a conference on a combination of its lead cancer drug along with radiationtherapy in treating melanoma, a type of skin cancer

** Data shows reolysin, when combined with radiationtherapy, effective in destroying cancer cells

** Reolysin was granted orphan drug status by U.S. FDA to treat a type of abdomen and fallopian tube cancer

** Orphan drug status is granted to drugs being developed to treat rare diseases; it gives drug developer various incentives including a 7-year marketing exclusivity

** Up to Wednesday's close, Oncolytics stock had gained 87 pct this year